

**CURRICULUM VITAE**

**CHARURUT SOMBOONWIT, MD, FACP**

Mailing Address:

1 Tampa General Circle, G318  
Tampa, Florida 33606

Phone: (813) 844-4187

**EDUCATION:**

1995                      Doctor of Medicine, with Honors  
1989-1995                Srinakharinwirot University, Bangkok, Thailand

**POSTGRADUATE TRAINING:**

2001-2003                Fellow, Infectious Diseases and Tropical Medicine University of  
South Florida Morsani College of Medicine, Tampa  
1998-2001                Resident, State University of New York at Brooklyn: affiliated  
program, St. John's Episcopal Hospital, Far Rockaway  
1996-1998                Resident, Ramathibodhi Hospital, Mahidol University, Bangkok,  
Thailand  
1995-1996                Rotating Internship, Choa Praya Yomaraj Hospital, Suphan Buri,  
Thailand

**CONTINUING PROFESSIONAL EDUCATION:**

2018                      Scientific Writing Workshop ( 6 hours), University of South  
Florida Morsani College of Medicine  
2011                      Behavioral Event Interview, University of South Florida Morsani  
College of Medicine  
2009                      Advanced High Resolution Anoscopy, American Society for  
Colposcopy and Cervical Pathology  
2007                      Graduate, Public Health Leadership Institute of Florida. Class XI,  
2007                      Graduate, Leadership Florida, Cornerstone Class XXV  
2005                      Certificate, Basic and Intermediate Public Health Risk  
Communication Training  
2005                      Certificate: Sterling Performance Excellence training in: Sterling  
Criteria, Knowledge Management and Using the Sterling Criteria  
for Performance Excellence and Balanced Scorecard

**MEDICAL LICENSURE:**

Florida, ME83811

**BOARD CERTIFICATIONS:**

2003-2023 American Board of Internal Medicine, Infectious Diseases  
2001-2022 American Board of Internal Medicine  
1998 ECFMG Certificate

**ACADEMIC APPOINTMENTS:**

2016-present Professor of Internal Medicine, University of South Florida Morsani College of Medicine, Division of Infectious Disease and International Medicine, Tampa  
2011-2016 Associate Professor of Internal Medicine, University of South Florida Morsani College of Medicine, Division of Infectious Disease and International Medicine, Tampa  
2006-2011 Assistant Professor of Internal Medicine, University of South Florida Morsani College of Medicine, Division of Infectious Disease and International Medicine, Tampa  
2003-2006 Clinical Assistant Professor, University of South Florida Morsani College of Medicine. Mentored and supervised medical students, pre-medical students, residents and fellows. Supervised rural health rotation for medical students.

**HOSPITAL APPOINTMENTS:**

2008-present Attending Physician, H. Lee Moffitt Cancer Center  
2005-present Attending Physician, Tampa General Hospital  
2018-2019 Attending Physician, Shriner's Crippled Children's Hospital  
2015-2019 Attending Physician, Florida Hospital Tampa  
2015-2019 Attending Physician, providing telehealth, Englewood Community Hospital  
2003-2011 Attending Physician, Shriner's Crippled Children's Hospital

**OTHER APPOINTMENTS:**

2021-present Chair, Appointments, Promotion and Tenure Committee, University of South Florida, Morsani College of Medicine

2020-present	Florida Medical Director, CDC/ Sylvia Ratelle STD/HIV Prevention Training Center
2020-2021	Vice Chair, Appointments, Promotion and Tenure Committee, University of South Florida, Morsani College of Medicine
2019-2021	Medical Director, Medical Health Administration, University of South Florida, Morsani College of Medicine
2018-2020	Member, Appointments, Promotion and Tenure Committee, University of South Florida, Morsani College of Medicine
2016-2021	Appointment Promotion and Tenure Committee, Department of Internal Medicine, University of South Florida, Morsani College of Medicine
2016-2020	Research Committee, University of South Florida, Morsani College of Medicine
2015-present	Associate Director, University of South Florida Morsani College of Medicine, Division of Infectious Disease and International Medicine, Tampa
2013-2014	Appointments, Promotion and Tenure Committee, University of South Florida, Morsani College of Medicine
2011-2016	SELECT Behavioral Event Interviewer
2010-2016	Medical Student Selection Committee, University of South Florida, Morsani College of Medicine
2009-2016	Interviewer, University of South Florida, Morsani College of Medicine Medical Student Admission
2006-present	Director, Communicable Diseases, Hillsborough County Health Department
2006-present	Director, Clinical Research, Hillsborough County Health Department
2005-2006	Senior Physician, Hillsborough County Health Department, Tampa, Florida. Direct HIV clinic, supervise disease control programs.
2003-2006	Senior Physician, Polk County Health Department, Bartow, Florida. Provided primary care for HIV patients, medical supervision for diseases control programs including STDs, tuberculosis and refugee health, immunization, epidemiology and hepatitis. Conducted quality assurance activities, and provided emergency responsibilities including hurricane response and disease outbreak.
2002-present	Faculty, Center of HIV Academic and Research Training – India (CHART-INDIA)
2001-2015	Teaching Faculty, Florida Caribbean Aids Education and Training Center (AETC)

## HONORS AND AWARDS:

2019	IDSAs Leadership Institute, Inaugural Class Scholar
2014	AAMC, Mid-Career Woman in Academic Medicine Professional Development Scholar
2012	Outstanding Alumni Award, Faculty of Medicine, Srinakharinwirot University, Thailand
2010	25 <sup>th</sup> Anniversary MEDSWU Honorable Award, Srinakharinwirot University, Thailand
2009	Elected Faculty Member, Alpha Omega Alpha Gamma Chapter, by vote of students and faculty
2009	Prudential-Davis Productivity Award for Hillsborough County Health Department Needle Stick Taskforce
2009-present	Citation, Best Doctors in America
2009	Citation, Rising Star by Tampa Bay Times and St. Petersburg Times
2008	Elected Faculty Member, Gold Humanism Society, University of South Florida, College of Medicine, Tampa
2008	Elected Fellow, American College of Physicians
1994	<i>Professor Wasant Jongjetana Award</i> , Merit award for the best clinical performance based on proficiency and doctor-patient relationship
1993	Best performance in Internal Medicine Clerkship and Pediatric Clerkship, Faculty of Medicine, Srinakharinwirot University

## EDUCATIONAL ACTIVITIES

### Undergraduate Medical Education

2014-present	Integrated Sciences in Infectious Disease (Course # MDT 8200A): Instructor, University of South Florida Morsani College of Medicine
2014-2018	SELECT, Professional Development (Course# BMS 6890) University of South Florida Morsani College of Medicine
2013-present	Doctoring 2, Clinical Education (Course # BMS 6826) University of South Florida Morsani College of Medicine
2013	Integrated Sciences in Infectious Disease (Course # MDT 8200A): Course Founder and Co-Director, University of South Florida Morsani College of Medicine
2011-2012	Doctoring 1, Clinical Education (Course # BMS 6825) University of South Florida Morsani College of Medicine

2010	Neutropenic Fever (EBCP 2, 2010): Facilitator. September 29, 2010
2007-present	Infections in ICU Electives (Course # MEL8363) University of South Florida Morsani College of Medicine
2007-2017	Scholarly Concentration in Biomedical Research (Course# BMS 6991) Co-Director, University of South Florida Morsani College of Medicine
2007-2010	Longitudinal Clinical Education (Course # BMS 6941) University of South Florida College of Medicine
2007	Physical Diagnosis (Course# BMS 6830), University of South Florida Morsani College of Medicine
2006	Colloquium in Infectious Diseases “Bad Air” series (Course# BMS 6920), University of South Florida Morsani College of Medicine
2006	K-30 Course (Course# GMS 6840, 2006) Lecture in Cultural and Diversity Issues in Clinical Research (K-30 Course), University of South Florida Morsani College of Medicine

### **Graduate Medical Education**

2008-present	Infectious Diseases Journal Club. Monthly Journal club for Infectious Diseases Fellows
2008-present	Introduction to Infectious Diseases, Infectious Disease Fellowship Training Annual Series, Annual Introductory lecture series for Infectious Diseases Fellows
2006-present	Annual Board Review Lecture Series for Fellows in Infectious Disease and International Medicine. Lecturer. University of South Florida, Tampa, Florida
2006-present	Infectious Diseases Basic Science Conference. Weekly lecture course for Infectious Disease Fellows, Internal Medicine residents, medical students
2006-present	Infectious Diseases Clinical Case Conference. Weekly case-based for Infectious Diseases Fellows, Internal Medicine residents, medical students
2006-present	Tampa General Hospital Microbiology Plate Rounds Series
2006-2011	Infectious Disease Fellows' Annual In-Service exam
2005-2006	Lunch and Learn HIV Medicine Lecture Series for Medical Students, Resident and Fellows in Infectious Disease, Tampa, Florida
2001-2003	Basic Science in Infectious Diseases Lecture Series (6 lectures/year), Tampa, Florida
2003	Developed Fellow Teaching Initiatives, University of South Florida, Division of Infectious Diseases, 2003

## **Fellows Trained**

Class 2021: Edward Drehs, MD, Jarelys Hernandez-Jimenex, MD, Codu Horn, DO, Zola Nlandu, MD, Hareeshe Singam, MD

Class 2020: Juhee Katzman, MD, Greg Mathew Teo, MD, Andrew Nguyen, DO, Sarah Sheyawish, MD, Vidhya Sabapathy, MD, Carlos Lopez-Perez, MD.

Class 2019: Cristina Garcia, MD, Mindy Sampson, DO, Shilah Moore-Prado, MD, Johonna Asquith, DO, Nathan Kraitman, MD

Class 2018: Misbahuddin Syed, MD, Adam Pettigrew, MD, Louise Gutierrez, MD, Muhammad Chughtai, MD, Garabet Akoghlanian, MD, Antheneh Addisu, MD, PhD

Class 2017: Shuchi Pandya, MD, Manuel Castro, MD, Olga Klinkova, MD, Robert Castro, MD, Marijesmar Gonzalez, MD

Class 2016: Flor Sanchez, MD, Kelly Kynaston, DO, Mihn Ho, DO, Kayley Tash, MD, Joseph Paolo, MD

Class 2015: Jane Mai, MD, Suganya Manivannan, MD, Ileana Acevedo, MD, Lysenia Mojica, MD, Jennifer Torres-Velasco, MD

Class 2014: Joseph Halliday, DO, Lily Jones DO, Mitsuya Katayama, MD, Nancy Rihana, MD, Rey J. Rivera, MD, Vivian Vega, MD

Class 2013: Christine Ayarza, MD, Pamela Noel, MD, Patrick Kenney, DO, Phuong Nguyen, MD

Class 2012: Joseph Katta, DO, Elias Maroun, MD, Georgina Nasr, MD, Tienchai Narach, MD, Luis Rosas, MD, Kevin Smith, MD

Class 2011: Moise Carrington, MD, Ulyee Choe, DO, Rachel Irby, MD, Elvis Castillo, MD

Class 2010: Sally Alrabaa, MD, Fariba Donovan, MD, PhD, Aliyah Baluch, MD, Dhanashree Kelkar, MD, Tran Phung, MD, Marela Velez, MD

Class 2009: Michelle Mizrachi, MD, Thiengi Oo, MD, Tri Pham, MD

Class 2008: Daniela Chiriboga, MD, Yagneshvari Patel, DO, Chakrapol Sriaroon, MD

Class 2007: Abigail Chandler, MD, Juan Diaz, DO, Anibal Maldonado, MD, Javier Marinez, MD

Class 2006: Ana Paula Velez, MD, Patricia Leon, MD, Igor Melynychuk, MD, Charles Philips, MD

## **Invited Presentations:**

Invited Speaker, Focus on Female Radio Health Topic: West Nile and Other Mosquito-Borne Encephalitis. May 2010

Invited Speaker, Focus on Female Radio Health Topic: HIV. December 2009

**Other Teaching:**

Member, Dissertation Committee. Doctoral Candidate in Medical Sciences: Lecia Brown, 2015-2017

Mentor, College Leadership, Leadership Florida. 2009-present

Mentor, Premedical Students, 2009-Present

Mentee: Irene Chen. Wayne State University School of Medicine Class 2022

Mentee: Seung-eun Jang. USF College of Medicine Class 2020

Mentees: Shed-laure Richardson, UF Class 2014

Mentees: Abigail Koch, MD, USF Class 2013

Mentees: Yuni Ann Yi, MD, UF Class 2013

**INVITED LECTURES**

**International:**

East and West Meet: Generations Converge. To create a pipeline of doctors by understanding new generation medical students. QS and Faculty of Medicine, Chulalongkorn University. Subject Focus Summit (Virtual), Bangkok, Thailand, 2020

Emerging Infectious Diseases: Annual Medical Conference, Khonkean Hospital, Khonkean, Thailand, 2016

HIV Update: International Medical Summit, Bangkok, Thailand, 2012

HIV Update: International Medical Summit, Bangkok, Thailand, 2010

HIV Update: International Medical Summit, Bangkok, Thailand, 2008

Annual HIV Management Symposium, Pune, India, 2003

Overview in HIV for Clinicians: JSS Medical College, Mysore, India, 2003

**National:**

Screening for Anal Cancer. Live Webinar for Project ECHO General HIV Session. Florida Caribbean AIDS Education and Training Center. Tampa Florida, April, 2014

HIV Highlights for Internists. Florida Chapter American College of Physicians, Annual Scientific Meeting, St. Pete Beach, Florida, October 2013

HPV Vaccination for HIV Infected Patients. Live Webinar for Project ECHO General HIV Session. Florida Caribbean AIDS Education and Training Center. Tampa Florida, September 2013

Management of Antiretroviral - Naïve HIV Infected Patients. Live Webinar for Florida Caribbean AIDS Education and Training Center. Tampa Florida, March 2013

Management of Antiretroviral - Naïve HIV Infected Patients. Podcast for Florida Caribbean AIDS Education and Training Center. Tampa Florida, July 2012

HIV and Cardiovascular Diseases. HIV Lunch-and-Learn, USF - St. Jude's Children Research Hospital VDO Conference, Tampa Florida, August 2011

HIV and Cardiovascular Diseases, Florida Caribbean AIDS Education and Training Center Annual Conference 2011, Orlando Florida, May 2011

Hepatitis Overview (Continuing Medical Education): Grand Rounds at Regency Medical Center, Winter Haven, Florida, 2004

Lecturer, HIV Update, Tampa General Hospital, 2002, 2003

Lecturer in *Travel Medicine*: Continuing Medical Education Program for primary care physicians, 2002

**Regional:**

HIV Highlights for Internists. USF Internal Medicine Grand Rounds, Tampa, Florida, October 2013

Lunch Lecture for Public Health Interest Group: "HIV: History and Prospective", Tampa, Florida, 2013

HIV for Primary Care Physician, Grand Round to Suncoast Medical Services. Tampa, Florida, March 2012

HIV 2011, Medical Grand Round, Orlando Health, Orlando, Florida January 2011

Lunch Lecture for Asia Pacific Medical Student Association: "Hepatitis B, the Global Menace" USF Health, Tampa, Florida, 2011

Lunch Lecture for Internal Medicine Interest Group: "HIV: History and Perspective", Tampa, Florida, 2011

MRSA: Worldwide Perspective, Local Issue, Annual Florida Public Health Association Conference, Orlando, Florida 2008

Lunch Lecture for Interfaith in Medicine Lecture Series: "Buddhism and Medicine", USF Health, Tampa, Florida, 2008

Quarterly Educational Programs for Immunization Program, Hillsborough County Health Department, Tampa, Florida, 2006-present

Quarterly Educational Programs for Epidemiologists, Hillsborough County Health Department, Tampa, Florida, 2006-present

Sexually Transmitted Diseases, Grand Rounds at Regency Medical Center, Winter Haven, Florida, 2005

Monthly Mortality Conference for Polk County HIV/AIDS Program Staff, Polk County Florida, 2004-2006

Monthly Multidisciplinary Conference for Patient Care Clinic, Polk County Health Department, Polk County Florida, 2004-2006

Didactic Lectures for epidemiologists in Weekly Epidemiology Conference, Polk County Health Department, Polk County, Florida 2003-2006



## RESEARCH AND SCHOLARLY ACTIVITIES

**PUBLICATIONS** (underlined when served as a corresponding or senior author)

### **Peer Reviewed Publications:**

1. Ahmed S, Algarin AB, Thadar H, Zhou Z, Taskin T, Vaddiparti K, Villalba K, Wang Y, Ennis N, Morano JP, **Somboonwit C**, Cook RL, Ibañez GE. Comorbidities among persons living with HIV (PLWH) in Florida: a network analysis. *AIDS Care*. 2022 Feb 16:1-9. doi: 10.1080/09540121.2022.2038363. Epub ahead of print. PMID: 35172664.
2. Kamara MTB, Richards VL, **Somboonwit C**, Park H, Seneadza NAH, Zhi Z, Jayaweera D, Thomas E, Cook RL. Self-reported hepatitis C(HCV) testing among people living with human immunodeficiency virus (PLWH). *Heliyon*. 2021 Aug 6;7(8):e07727. doi: 10.1016/j.heliyon.2021.e07727. PMID: 34409188; PMCID: PMC8361055.
3. Ibañez GE, Zhou Z, Algarin AB, Ayala DV, Spencer EC, **Somboonwit C**, Teo GM, Cook RL. Incarceration History and HIV Care Among Individuals Living with HIV in Florida, 2014-2018. *AIDS Behav*. 2021 May 6. doi: 10.1007/s10461-021-03250-8. Epub ahead of print. PMID: 33959828.
4. Hernandez JM, Quarles R, Lakshmi S, Casanas B, Eatrides J, McCoy E, **Somboonwit C**. Pancytopenia and Profound Neutropenia as a Sequela of Severe SARS-CoV-2 Infection (COVID-19) With Concern for Bone Marrow Involvement. *Open Forum Infect Dis*. 2021 Jan 18;8(2):ofab017. doi: 10.1093/ofid/ofab017. PMID: 33604404; PMCID: PMC7880265.
5. Joseph V, Jones A, Canidate S, Mannes Z, Lu H, Ennis N, Ibanez G, **Somboonwit C**, Cook R. Factors associated with current and severe pain among people living with HIV: results from a statewide sample. *BMC Public Health*. 2020 Sep 18;20(1):1424. doi: 10.1186/s12889-020-09474-y. PMID: 32948167; PMCID: PMC7501653.
6. Lewis MA, Harshbarger C, Bann C, Burrus O, Peinado S, Garner BR, Khavjou O, Shrestha RK, Karns S, Borkowf CB, Zulkiewicz BA, Ortiz A, Galindo CA, DallaPiazza M, Holm P, Marconi VC, **Somboonwit C**, Swaminathan S; Positive Health Check Study Team. Positive Health Check evaluation: A type 1 hybrid design randomized trial to decrease HIV viral loads in patients seen in HIV primary care. *Contemp Clin Trials*. 2020 Sep;96:106097. doi: 10.1016/j.cct.2020.106097. Epub 2020 Jul 29. PMID: 32738408.
7. Ibañez GE, Zhou Z, **Somboonwit C**, Cook CL, et al. The Florida Cohort study: methodology, initial findings and lessons learned from a multisite cohort of people living with HIV in Florida [published online ahead of print, 2020 Apr 3]. *AIDS Care*. 2020;1-9. doi:10.1080/09540121.2020.1748867

8. Fleming J, Berry SA, Moore RD, Nijhawan A, **Somboonwit C**, Cheever L, Gebo KA; HIV Research Network. U.S. Hospitalization rates and reasons stratified by age among persons with HIV 2014-15. *AIDS Care*. 2019 Dec 8;1-10. doi: 10.1080/09540121.2019.1698705. [Epub ahead of print] PubMed PMID: 31813269.
9. Wang L, Krebs E, Min JE, Nijhawan A, **Somboonwit C**, Aberg J, Moore RD, Gebo K, Nosyk B, for the HIV Research Network. Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study. *Lancet HIV*. 2019 Aug;6(8):e531-e539. doi:10.1016/S2352-3018(19)30148-1. Epub 2019 Jul 11. PubMed PMID: 31303557.
10. Fleming J, Aberg J, **Somboonwit C**, Moore RD, Gebo K, for the HIV Research Network. Low Level Viremia and Virologic Failure in Persons with HIV Infection Treated with Antiretroviral Therapy. *AIDS*. 2019 Jul 10. doi: 10.1097/QAD.0000000000002306. [Epub ahead of print] PubMed PMID: 31306175.
11. Mannes ZL, Burrell LE 2nd, Ferguson EG, Zhou Z, Lu H, **Somboonwit C**, Cook RL, Ennis N. The association of therapeutic versus recreational marijuana use and antiretroviral adherence among adults living with HIV in Florida. *Patient Prefer Adherence*. 2018 Jul 27;12:1363-1372. doi: 10.2147/PPA.S167826. eCollection 2018. PubMed PMID: 30100713; PubMed Central PMCID: PMC6067624.
12. **Somboonwit C**, Menezes LJ, Holt DA, Sinnott JT, Shapshak P. Current views and challenges on clinical cholera. *Bioinformatics*. 2017 Dec 31;13(12):405-409. doi: 10.6026/97320630013405. eCollection 2017. PubMed PMID: 29379258; PubMed Central PMCID: PMC5767916.
13. Shapshak P, **Somboonwit C**, Sinnott JT. Artificial Intelligence and Virology-quo vadis. *Bioinformatics*. 2017 December 31; 13(12):410-411. doi: 10.6026/97320630013410. eCollection 2017. PubMed PMID: 29379259; PubMed Central PMCID: PMC5767917.
14. Shapshak P, **Somboonwit C**, Cao S, Sinnott JT. Cholera host response gene networks: preliminary studies. *Bioinformatics*. 2017 Oct 31;13(10):347-351. doi:10.6026/97320630013347. eCollection 2017. PubMed PMID: 29162968; PubMed Central PMCID: PMC5680717.
15. Cook RL, Zhou Z, Kelso-Chichetto NE, Janelle J, Morano JP, **Somboonwit C**, Carter W, Ibanez GE, Ennis N, Cook CL, Cohen RA, Brumback B, Bryant K. Alcohol consumption patterns and HIV viral suppression among persons receiving HIV care in Florida: an observational study. *Addict Sci Clin Pract*. 2017 Sep 27;12(1):22. doi: 10.1186/s13722-017-0090-0. PubMed PMID: 28950912; PubMed Central PMCID: PMC5615807.

16. Cameron MC, Katayama M, Patel NS, Shenefelt PD, **Somboonwit C**. Chronic Tender Ulcers on the Calf and Both Forearms. *Skinmed*. 2017 Apr 1;15(2):149-151. eCollection 2017. PubMed PMID: 28528615.
17. Achhra AC, Mocroft A, Ross M, Ryom-Nielson L, Avihingsanon A, Bakowska E, Belloso W, Clarke A, Furrer H, Lucas GM, Ristola M, Rassoool M, Ross J, **Somboonwit C**, Sharma S, Wyatt C; INSIGHT START Study Group. Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial. *Int J Antimicrob Agents*. 2017 Jun 28. pii:S0924-8579(17)30230-3. doi: 10.1016/j.ijantimicag.2017.04.021.
18. Berry SA, Fleishman JA, Yehia BR, Cheever LW, Hauck H, Korthuis PT, Mathews WC, Keruly J, Nijhawan AE, Agwu AL, **Somboonwit C**, Moore RD, Gebo KA; HIV Research Network. Healthcare Coverage for HIV Provider Visits before and after Implementation of the Affordable Care Act. *Clin Infect Dis*. 2016 May 3. pii:ciw278. [Epub ahead of print] PubMed PMID: 27143660
19. Achhra A, Mocroft A, Ross M, Ryom L, Lucas G, Furrer H, Neuhaus J, **Somboonwit C**, Kelly M, Gatell J, Wyatt C; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. *HIV Med*. 2015 Apr;16 Suppl 1:55-63.
20. Crowell TA, Gebo KA, Blankson JN, Korthuis PT, Yehia BR, Rutstein RM, Moore RD, Sharp V, Nijhawan AE, Mathews WC, Hanau LH, Corales RB, Beil R, **Somboonwit C**, Edelstein H, Allen SL, Berry SA; for the HIV Research Network. Hospitalization Rates and Reasons among HIV Elite Controllers and Persons with Medically Controlled HIV Infection. *J Infect Dis*. 2014 Dec 15. pii: jiu809. [Epub ahead of print] PubMed PMID: 25512624.
21. Young LC, Roediger MP, Grandits G, Baker J, **Somboonwit C**, Williams I, Lundgren JD, Neaton JD, Soliman EZ. Relationship between inflammatory and coagulation biomarkers and cardiac autonomic function in HIV-infected individuals. *Biomark Med*. 2014;8(9):1073-83.
22. Zetterberg E, Neuhaus J, Baker JV, **Somboonwit C**, Llibre JM, Palfreeman A, Chini M, Lundgren JD; INSIGHT SMART Study Group. Platelet count kinetics following interruption of antiretroviral treatment. *AIDS*. 2013 Jan 2;27(1):59-68
23. Bahner I, **Somboonwit C**, Pross S, Collins R, Saporta S. Teaching Science Through Biomedical Research in An Elective Curriculum. *Medical Science Educator*, 2012;22(3s):143-146
24. Shapshak P, Duncan R, Kanguane P, **Somboonwit C**, Sinnott JT, Commins D, Singer E, Levine A. HIV Associated Dementia and HIV Encephalitis II: Genes

on Chromosome 22 Expressed in Individually Microdissected Globus Pallidus Neurons (Preliminary analysis). *Bioinformation* 2011; 6(5): 183-186

25. Shapshak P, **Somboonwit C**, Sinnott JT, Commins D, Singer E, Levine AJ. Gene-Chromosome Locations of Neuropsychiatric Diseases. *Bioinformation* 2011; 7(7): 366-368
26. Mouzakis J, **Somboonwit C**, Lakshmi S, Rumbak M, Sinnott JT, Cherpelis B, Keshishian J. Levamisole Induced Necrosis of the Skin and Neutropenia Following Intranasal Cocaine Use: A Newly Recognized Syndrome. *J Drugs Dermatol* 2011 Oct 1;10(10):1204-7
27. Shapshak P, Duncan R, Duran EM, Farinetti F, Minagar A, Commins D, Rodriguez H, Chiappelli F, Kanguane P, Levine AJ, Singer E, **Somboonwit C**, Sinnott JT. Gene Expression for HIV-Associated Dementia and HIV Encephalitis in Microdissected Neurons: Preliminary Analysis. *Neurobehavioral HIV Medicine* 2011; 3:53-78
28. Shapshak P, Chiappelli F, **Somboonwit C**, Sinnott JT. The Influenza Pandemic of 2009: Lessons and Implications. *Mol Diagn Ther.* 2011 Apr 1;15(2):63-81
29. Chiappelli F, **Somboonwit C**, Sinnott J, Shapshak P. Influenza 2009 Pandemic: Immunology. *Bioinformation.* 2011 Mar 2; 6(1):39-40
30. Barkhordarian A, Iyer N, Shapshak P, **Somboonwit C**, Sinnott JT, Chiappelli F. Influenza 2009 Pandemic: Cellular Immunemediated Surveillance Modulated by TH17 & Tregs. *Bioinformation* 2011 Mar 2;6(1):39-40
31. Shamini G, Ravishandran M, Sinnott JT, **Somboonwit C**, Sidhu H, Shapshak P, Kanguane P. Structural Inferences for Cholera Toxin Mutations in *Vibrio cholerae*. *Bioinformation* 2011 Mar; 6(1): 1-9
32. Sinnott JT, **Somboonwit C**, Oxner A. *Clostridium tetani* in a Haitian Refugee. *Clin Microbiol Newsl* 2011 Mar; 33(5): 37-39
33. Sowmya G, Shamini G, Anita S, Sakharkar M, Mathura V, Rodriguez H, Levine A, Singer E, Commins D, **Somboonwit C**, Sinnott JT, Sidhu H, et al. HIV-1 Envelope Accessible Surface and Polarity: Clade, Blood and Brain. *Bioinformation* 2011 March 6(2):48-56
34. Pham T, Alrabaa ST, Hung L, **Somboonwit C**, Montero JA. The HIV Virologic Outcomes of Different Interventions among HAART Experienced Patients with Two Consecutive Detectable Low-Level Viremia. *JAPAC* 2011 Jan-Feb;10(1):54-6
35. Soliman EZ, Lundgren JD, Roediger MP, Duprez DA, Temesgen Z, Bickel M, Shlay J, **Somboonwit C**, Reiss P, Stein JH, Neaton JD, on behalf of the SMART/INSIGHT study group. Association between Ritonavir Boosted Protease Inhibitors with QTc and PR Interval Durations in the Strategies for

Management of Antiretroviral Therapy (SMART) Trial. *AIDS* 2011 Jan 28;25(3):367-77

36. Shapshak P, Pandjassarame K, Fujimura RK, Commins D, Chiappelli F, Singer E, Levine A, Minagar A, Novembre F, **Somboonwit C**, Nath A, Sinnott JT. NeuroAIDS Review. Editorial. *AIDS* 2011; 25:123-141
37. **Somboonwit C**, Kurtyka D, Velez AP. Abacavir and Lamivudine Combination. *Expert Opin Drug Metabl Toxicol* Dec 2009; 5(12):1599-606
38. Shapshak P, **Somboonwit C**, Drumright LN, Frost S DW, et al. Molecular and Contextual Markers of HCV and Drug Abuse. *Mol Diagn Ther* 2009; 13(3):153-79
39. **Somboonwit C**, Tash K, Donovan FM, Houston SH. Infectious Complications of Solid Organ Transplantation. *Infect Med* 2009; 26; 41-46
40. Shapshak P, Tellinghuisen T, Scott WK, Duncan R, McCoy C, Page JB, **Somboonwit C**, Giunta B, Fernandez F. Molecular Mechanisms in HCV and Drug Abuse. *Bioinformation* 2008; 3(1): 53–57
41. Shapshak P, **Somboonwit C**, Chiappelli F, Commins D, Singer E, Levine AJ, Minagar A, Pellionisz AJ. Molecular Epigenetics, Chromatin, and NeuroAIDS/HIV: Translational Implications. *Bioinformation* 2008; 3(1):53-7
42. Giunta B, **Somboonwit C**, Nikolic WV, Rrapo E, Tan J, Shapshak P, Fernandez F. Psychiatric Implications of Hepatitis-C Infection. *Crit Rev Neurobiol* 2007; 19(2-3): 79-118
43. Rungruanghiranya S, **Somboonwit C**, Kanchanapoom T.J. Acinetobacter Infection in the Intensive Care Unit. *Infect Dis Antimicrobial Agents* 2005; 22:77-92
44. Nadler JP, Wills T, **Somboonwit C**. Anemia Prevalence and Associated Risk Factors in a Single-Center Ambulatory HIV Clinical Cohort. *AIDS Read* 2004; 14:305-10
45. Haight DO, **Somboonwit C**, Degryse A. West Nile Viruses: Clinical and Diagnostic Considerations. *Clin Microbiol Newsl* 2003; 25:149-51
46. **Somboonwit C**, Greene JN. Diagnostic Methodologies for Diagnosis of Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Patient. *Semin Respir Infect* 2002; 17:151-7

### **Book Chapters:**

1. **Somboonwit C**, Vazquez L, Menezes LJ. HIV and Injection Drug Use: New Approaches to HIV Prevention. In Shapshak P, Balaji S, **Somboonwit C**,

- Chiappelli F, Menezes L, Kanguane P, Sinnott J. *Global Virology III: Virology in the 21<sup>st</sup> Century*. New York, Springer, 2019.
2. Menezes LJ, Vazquez L, Mohan CK, Somboonwit C. Eliminating cervical cancer: A role for artificial intelligence. In Shapshak P, Balaji S, **Somboonwit C**, Chiappelli F, Menezes L, Kanguane P, Sinnott J. *Global Virology III: Virology in the 21<sup>st</sup> Century*. New York, Springer, 2019.
  3. **Somboonwit C**, Montero JA, Sinnott JT, Shapshak P. Antiretroviral Therapy and NeuroAIDS. In Shapshak P, Singer E, Levine A, Sinnott JT, Somboonwit C. *Global Virology II: HIV and NeuroAIDS*. New York, Springer, 2017.
  4. Elkomy FF, Levine AJ, Singer E, **Somboonwit C**, Wills TS, Tash KM, Sinnott JT, Alrabaa S, Addissu A, Rodriguez H, Chiappelli, Kazic T, Shapshak P. Neutroal Apoptotoc in H(V-Associated Dementia, Alzheimer's Disease, Parkinson's Disease and Huntington's Disease. *Global Virology II: HIV and NeuroAIDS*. New York, Springer, 2017.
  5. Rodriguez HE, Lakshmi S, **Somboonwit C**, Oxner A, Guerra L, Addissu A, Guitierrez, Sinnott JT, Nilofer C, Kanguane P, Shapshak P. Gene Therapy Blueprints for NeuroAIDS. *Global Virology II: HIV and NeuroAIDS*. New York, Springer, 2017.
  6. **Somboonwit C**, Sinnott JT, Shapshak P. XMRV: Emerging Human Infection or False Alarm. In Shapshak P, Kuhns JH, Sinnott JT, Somboonwit C. *Global Virology*. New York, Springer, 2015.
  7. Shapshak P, **Somboonwit C**, Foley BT, Alrabaa SF, Wills TS, Sinnott JT. Zika Virus. In Shapshak P, Kuhns JH, Sinnott JT, Somboonwit C. *Global Virology*. New York, Springer, 2015.
  8. Alrabaa SF, **Somboonwit C**, Shpashak P. West Nile Virus. In Shapshak P, Kuhns JH, Sinnott JT, Somboonwit C. *Global Virology*. New York, Springer, 2015.
  9. **Somboonwit C**, Menezes LJ. Kaposi's sarcoma (KS). In J Beal, J Orrick, K Alfonso, M Rathore (eds.), *HIV/AIDS Primary Care Guide*. Norfolk, CT. Crown House Publishing Company LLC, 2006. Pp. 369-375
  10. **Somboonwit C**. Viral Hemorrhagic Fever. In *APIC Text of Infection Control & Epidemiology*. Washington, DC: Association for Professionals in Infection Control and Epidemiology, 2005. Pp. 90(1-11)

11. **Somboonwit C**, Poklepovic A, Irvine L, Sinnott JT. Infectious disease aspects of viral hemorrhagic fever. In: Soule BM ed. *The American Practitioner in Infection Control*. St. Louis: Mosby-Year Book, Inc., 2004
12. **Somboonwit C**. Infections in Lung Cancer Patients. In Greene JN (ed.), *Infections in Cancer Patients*. New York: Marcel Dekker, 2004. Pp. 187-197
13. **Somboonwit C**. Infections in Head and Neck Cancer Patients. In Greene JN (ed.), *Infections in Cancer Patients*. New York: Marcel Dekker, 2004. Pp. 177-185

### **Books:**

1. Shapshak P, Balaji S, **Somboonwit C**, Chiappelli F, Menezes L, Kanguane P, Sinnott J. *Global Virology III: Virology in the 21<sup>st</sup> Century*. New York, Springer, 2019.
2. Shapshak P, Levine AJ, Foley BT, **Somboonwit C**, Singer E, Chiappelli F, Sinnott JT. *Global Virology II: HIV and NeuroAIDS*. New York, Springer, 2017.
3. Shapshak P, Sinnott JT, **Somboonwit C**, Kuhns JH. *Global Virology*. New York, Springer, 2015.

### **Other Publications:**

1. **Somboonwit C**. Letter to Editor, Scoring the point, Tampa Tribune, September 21, 2011
2. **Somboonwit C**. Letter to Editor, HPV vaccine and politics, misinformation unhealthy. St. Petersburg Times, September 20, 2011
3. **Somboonwit C**. Letter to Editor, Remember women's issues. St. Petersburg Times, October 31, 2011
4. **Somboonwit C**, Alrabaa S. Carelink. Volume12, Issue 5. April 25, 2011. Found at [http://www.faetc.org/PDF/Newsletter/Newsletter-Volume14-2013/HIVCareLink-03-26-13-v14\\_i05-DHHSGuidline.pdf](http://www.faetc.org/PDF/Newsletter/Newsletter-Volume14-2013/HIVCareLink-03-26-13-v14_i05-DHHSGuidline.pdf)
5. Wu A, Shah M, **Somboonwit C**. Pre-exposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men Interim Guidance. Carelink. Volume12, Issue 5. April 25, 2011. Found at [http://www.faetc.org/PDF/Newsletter/Newsletter-Volume12-2011/HIVCareLink-04-25-11-v12\\_i05-PrePHIVmen.pdf](http://www.faetc.org/PDF/Newsletter/Newsletter-Volume12-2011/HIVCareLink-04-25-11-v12_i05-PrePHIVmen.pdf)

6. **Somboonwit C**, Smith KM. Prevention and Treatment of Opportunistic Infections (OIs) in HIV-Infected Adult and Adolescence Guideline Summary. CareLink. Volume 12, Issue 4. March 22,2011.Found at: [http://www.faetc.org/PDF/Newsletter/Newsletter-Volume12-2011/HIVCareLink-03-22-11-v12\\_i04-OI\\_Update.pdf](http://www.faetc.org/PDF/Newsletter/Newsletter-Volume12-2011/HIVCareLink-03-22-11-v12_i04-OI_Update.pdf)
7. **Somboonwit C**. Ask the Expert: What are the latest advances in HIV treatment? Tampa Tribune 4You. July 17, 2010
8. **Somboonwit C**, Donovan F. St. Louis Encephalitis. *Emedicine*. Epub 2009 Jan 29. Found at: <http://emedicine.medscape.com/article/233710-overview>
9. Gompf S, **Somboonwit C**. Rabies. *Emedicine.com* 2008, October 3. Found at: <http://emedicine.medscape.com/article/220967-overview>
10. Emmanuel SU, Goldstein-Hart C, **Somboonwit C**, Haight DO. Salmonella meningitis: Possible association with turtle. *Epi Update*, Florida Department of Health, Bureau of Epidemiology. Jan 2006
11. Hamilton K, **Somboonwit C**, Haight D. Surviving and Understanding Meningitis. ABC News On-line. January 29, 2007. Found at: <http://abcnews.go.com/Health/story?id=2827338&page=1>

## **ABSTRACT PRESENTATIONS:**

### **Poster Presentations:**

1. Kongpakpaisarn K, Aslam S, Tariq M, Mhaskar R, Shin D, Bohra C, **Somboonwit C**. Predictors of Recurrent Infective Endocarditis in Intravenous Drug Users.(Poster presentation, poster ID 170). <https://idweek.org/> Presented at IDWeek2019, October 2-6, 2019. Washington DC, 2019.
2. Teo GM, Nagaraj S, Sunku N, Aslam S, Mhaskar R, Chen L, Zhou Z, Cook R, Morano J, **Somboonwit C**. The Impact of Recent Incarceration on Post-Release HIV Linkage to Care and Risk-Taking Behaviors in the Setting of Enhanced Linkage to Care Policies in Florida. (Poster presentation, poster ID 1310). <https://idweek.org/> Presented at IDWeek2019, October 2-6, 2019. Washington DC, 2019.
3. Teo GM, Nagaraj S, Sunku N, Aslam S, Mhaskar R, Chen L, Zhou Z, Cook R, Morano J, **Somboonwit C**. Comparison of Access and Linkage to Care Among People Living with Human Immunodeficiency Virus When Enrolled in Florida AIDS Drug Assistance Program (ADAP). (Poster presentation, poster ID 1317). <https://idweek.org/> Presented at IDWeek2019, October 2-6, 2019. Washington DC, 2019.
4. Flemming J, Gebo K, Rutstein R, Matthews WC, Aberg J, **Somboonwit C**, Cheever LW, Moore RD. Low Level Viremia and Virologic Failure in Persons with HIV Treated with ART. ( poster presentation, poster ID 2171) <http://www.croiconference.org/> . Presented at CROI, March 4-7,2019. Seattle, WA, 2019.



5. Flemming J, Berry S, Moore R, Nijhawan A, **Somboonwit C**, Cheever L, Gebo K. Hospitalizations Rates and Reasons Stratified by Age among Persons with HIV 2014-2015. (poster presentation) <http://www.idweek.org>. Presented at IDWeek; October 3-7, 2018; San Francisco, CA 2018.
6. Wills T, Friedrich M, Beal J, **Somboonwit C**, Mcintosh S, Bork A, Tinsley M, Cajina A, Belton P, Xavier J, Doshi R, Boyd R, Solomon N. Implementing Hepatitis C Treatment Programs in Comprehensive HIV Clinics: The Health Resources and Services Administration (HRSA) Special Projects of National Significance (SPNS) Hepatitis C Treatment Expansion Initiative (poster presentation) <http://www.idweek.org>. Presented at IDWeek; October 8-12, 2014; Philadelphia, PA, 2014.
7. Choe U, Nasr G, Shah M, **Somboonwit C**, Montero J, Chen R, Menezes, L. Virologic Outcomes Associated with Ritonavir-boosted Atazanavir and Concomitant Acid Suppression Therapy. Infectious Diseases Society of America 2011 Annual Meeting; October 2011 Pham T, Montero J, **Somboonwit C**. Comparison of Virologic Outcome in Different Treatment Approaches for HIV Patients with Persistent Low-Level Viremia. Presented at 2009 Bristol-Myers-Squibb Virology Fellow Program, Philadelphia, 2009
8. Menezes L, D'Souza KR, D'Souza KM, **Somboonwit C**, Amin S, Sinnott J. A socio-historical construction of the AIDS epidemic in India. Abstract: MOPE0724. Presented at the XVI International AIDS Conference. Toronto, 2006
9. Nadler JP, Wills TS, **Somboonwit C**, et al. Anemia prevalence among HIV patients: antiretroviral therapy and other risk factors: abstract 1151. 2<sup>nd</sup> International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, 2003
10. **Somboonwit C**, Greene JN, Haight DO. Pulmonary *Penicilliosis Marneffeii* in a Cancer Patient without Endemic Area Exposure: A Case Report. Focus on Fungal Infections. Phoenix, 2002
11. Sinnott JT, **Somboonwit C**. *Food poisoning and Irradiation*. The 6<sup>th</sup> Gamma Processing Seminar, Ottawa, 2002

**Platform Presentation:**

1. **Somboonwit C**. NeuroAIDS. Abstract and Oral Presentation (accepted), the 3<sup>rd</sup> Annual World Congress of Microbes, Wuhan, China, July 2013 (unable to present due to medical reason)

**Ad hoc Manuscript Reviewer:**

International Journal of STD and AIDS 2013



2. Florida Cohort Funded: \$ 15,000 2014-2018  
A longitudinal cohort study in collaboration with the University of Florida, will enroll up to 1,500 participants with HIV infection and an additional 200 without HIV across the state of Florida.
3. EMR 200147-500 Funded: \$305,760 2013-2014  
A prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate whether EGRIFTA® (tesamorelin for injection), 2 mg once daily SC, increases the risk of development or progression of diabetic retinopathy when administered to HIV-infected subjects with abdominal lipohypertrophy and concomitant diabetes
4. MK 96615 Funded: NA 2013-2013  
Quality of Life of HIV-Infected Patients Switched to Raltegravir versus other Antiretroviral Regimens
5. IMPAACT 1077HS Funded: \$200,400 2010-2016  
HAART Standard Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)
6. Pfizer- 6115A1-4007-US Funded: \$120,000 2010-2011  
Distribution of PCV 13 Serotype *Streptococcus Pneumoniae* in Adults 50 Years and Older Presenting to Select US Hospitals with Radiographically-Confirmed Community-Acquired Pneumonia (CAP) ( 28 subjects enrolled)
7. Schering- P04875(A673DL) Funded: \$ 239,173 2009- 2011  
Efficacy and Safety of Vivriviroc in HIV-Infected Treatment Naive Subject
8. Merck-IISP 33107 (A673CG) Funded: \$ 74,561 2008-2011  
A Pilot, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Raltegravir versus NRTIs as a Backbone in HIV-Infected Patients Switched from a Stable Boosted PI Regimen
9. Funding Source: NA Funded: NA 2007-2010  
HIV and Cardiovascular Risks in an Urban Setting a retrospective study for cardiovascular risk factors prevalent among HIV positive patients receiving care in an urban Health Department located in Hillsborough County, FL
10. Tibotec - TMC114-C211(A673Z4) Funded: \$19,373 2006-2008  
A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir (ARTEMIS) (1 Subject enrolled)
11. DAIDS – SMART Funded: \$331,984 2006-2007  
A Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy. SMART CPCRA 065 (26 Subjects enrolled)

- |   |                   |           |
|---|-------------------|-----------|
| 12. Archilion (ACH443-015)  | Funded: \$2,955   | 2005-2006 |
| Phase II, Randomized, Blinded, 12-Week Comparison of Elvucitabine in Combination with Efavirenz and Tenofovir Versus Lamivudine in Combination with Efavirenz and Tenofovir (0 Subjects enrolled) |                   |           |
| 13. Schering-P04889 (A673BK)  | Funded: \$116,612 | 2006-2011 |
| Vicriviroc in Combination Treatment with an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects  |                   |           |
| 14. John Hopkins University   | Funded: \$316,507 | 2006-2016 |
| Pilot Study for a Multisite HIV/AIDS Clinical and Resource Use Data   |                   |           |

**Current Studies - Co-Investigator**

(Serve as director of clinical research, Hillsborough County Health Department, active in recruiting studies, acting as liaison between USF Infectious Disease researchers and sponsors and regulatory agencies. Location for all of the following research activities: USF/Hillsborough County Health Department or USF/Tampa General Hospital)

- |   |  |                |              |
|---|--|----------------|--------------|
| 1 | iTECH-ATN 142<br>Promoting PrEP Adherence Through a Social Networking, Gamification and Adherence Support App.   | PI: Emmanuel P | 2020-present |
| 2 | iTECH-ATN 138<br>, ATN-138 YouTHrive ( Connecting Youth to Optimize ART Adherence Using a Mobile-optimized Website)  | PI: Emmanuel P | 2020-present |
| 3 | NIMH/UNC-ToughTalk<br>Using Artificial Intelligence in Increase HIV Disclosure Among Young MSM   | PI: Emmanuel P | 2020-present |
| 4 | NIAAA -U24<br>Southern HIV Alcohol Research Consortium. USF is contracted to continue the work of Florida Cohort, a longitudinal cohort study in collaboration with the University of Florida.   | PI: Morano J   | 2018-2021    |
| 5 | Florida Department of Health<br>#7ZK19<br>University of South Florida Integrated Clinical Trial Network Structuring and Enhancement for Execution of Zika Virus Vaccine and Diagnostic Clinical Trials, and testing of other Emerging Infectious Disease (EID) Solutions for Florida. [Zika Clinical Research Network (ZiCRN)] | PI: Casale T   | 2017-present |

**Past Studies-Co-Investigator**

(Location for all of the following research activities: USF/Hillsborough County Health Department)

1. AMG 145 PI:Morano J 2016-2020  
BEIJERINCK: evolocumab effect on LDL-C lowering in subjects with human immunodeficiency virus and increased cardiovascular risk
2. GS-US 380-4458 PI: Morano 2018-2019  
Study on Fixed Dose Combination of Bictegrovir/ Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir+Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naïve, HIV-1 and Hepatitis B co-infected adults.
3. MK-1439-018 PI: Montero J 2015-2019  
A Phase 3 Multicenter, Double-blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each in Combination with TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1 Infected Subjects
4. MK-1439-007-07 PI: Montero J 2013-2019  
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA™ Versus Efavirenz Plus TRUVADA™ in Antiretroviral Treatment-Naïve, HIV-1 Infected Patients
5. GSK-204863 TANGO PI: Casanas 2017-2018  
A Phase 3, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1-infected adults who are virologically suppressed
6. GS-US-292-1246 PI: Wills T 2015-2018  
A Phase 3b, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide versus Dolutegravir/Lamivudine/Abacavir in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
7. GS-US-366-1216 PI: Wills T 2015-2018  
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
8. GS-US-366-1160 PI: Wills T 2015-2018  
A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to

Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects

- 9 MK-1439-018 PI: Montero J 2015-2018  
A Phase 3 Multicenter, Double-blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each in Combination with TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1 Infected Subjects
10. MK-1439-007-07 PI: Montero J 2013-2018  
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA™ Versus Efavirenz Plus TRUVADA™ in Antiretroviral Treatment-Naïve, HIV-1 Infected Patients
11. GS-US-292-0111 PI: Wills T 2013-2018  
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide versus Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults
12. GS-US-292-0104 PI: Wills T 2013-2018  
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide versus Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults
- 13 GS-US-292-0109 PI: Wills T 2013-2018  
Gilead. A Phase 3, Open Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically Suppressed, HIV 1 Positive Subjects
15. GS-US-292-0112 PI: Wills T 2013-2018  
Gilead. A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal Impairment
16. GS-US-292-0117 PI: Wills T 2013-2018  
A Phase 3, Two Part Study to Evaluate the Efficacy of Tenofovir Alafenamide versus Placebo Added to a Failing Regimen Followed by Treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
17. GS-US- 292-0119 PI: Wills T 2013-2018  
A Phase 3 Open-Label Study to Evaluate Switching from Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single

Tablet Regimen (STR) plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

18. GS-US-292-1089 PI: Wills T 2013-2018  
Gilead A Phase 3, Randomized, Open-Label, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF
19. MK-1439-007-07 PI: Montero J 2013-2018  
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA™ Versus Efavirenz Plus TRUVADA™ in Antiretroviral Treatment-Naïve, HIV-1 Infected Patients
- 18.. GSK ING 117172 PI: Casanas B 2013-2018  
A Phase IIIb, randomized, open-label study of the safety and efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in HIV-1 infected antiretroviral therapy naïve women
- 19.GS-US-183-0130 PI:Wills T 2008-2014  
A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults
- 20.Merck-002-00 MK-4315A PI: Alrabaa S 2012-2014  
A Phase III, Randomized, Double-blinded, Placebo-Controlled Study of Efficacy and Tolerability of a Single Infusion of MK-6072( Human Monoclonal Antibody to C difficile toxin B) and MK-3415A(Human Monoclonal Antibody to C difficile toxin A and B) in Patients receiving Antibiotics Therapy for C difficile Infection( MODIFY II)
21. Tibotec (TMC278-C204) PI: Casanas B 2005-2008  
A Phase IIb, Randomized, Partially Blinded, Dose-Finding Trial of TMC278 in Antiretroviral Naïve HIV-1 Infected Subjects
22. Tibotec (TMC278-209) PI: Casanas B 2008-2010  
A Phase III, Randomized, Double-Blind Study of TMC278 25 mg once daily in Combination with a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-Naïve HIV-1 Infected Subjects
23. Pfizer A 4001095 PI: Montero J 2011-2014  
A Multicenter, Randomized, Double Blind, Comparative Trial of Maraviroc + Darunavir/Ritonavir vs Emtricitabine/Tenofovir + Darunavir/RTV for the treatment of Antiretroviral Naïve HIV Infected Patients with CCR5 Tropic HIV 1

24. AMC PROTOCOL #072                      PI: Emmanuel P                      2011-2013  
Protective Effect of Quadrivalent Vaccine in Young HIV-positive Males who have Sex with Males.
25. Gilead- GS-US-236-0102                      PI: Wills T                      2010-2014  
A Phase 3, Randomized, Double Blinded Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
26. Gilead-GS-US 236-0103                      PI:Wills T                      2010-2013  
A Phase 3, Randomized, Double Blinded Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 versus Ritonavir- Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
27. Gilead-GS-US-236-0114                      PI:Wills T                      2012-2013  
A Phase 3, Randomized, Double Blinded Study to Evaluate the Safety and Efficacy of GS-9350 Boosted Atazanavir versus Ritonavir-Boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
28. Napo (NP303-101)                      PI: Casanas B                      2006-2009  
Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Two- Stage Study to Assess the Efficacy and Safety of Crofelemer 125mg, 250mg, and 500mg for HIV-Associated Diarrhea [ADVENT TRIAL]
29. Augouron/Pfizer(A4001027)                      PI: Montero J                      2005-2013  
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination with Optimized Background Therapy versus Optimized Background Therapy along for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects
30. Tibotec (TMC125-C217)                      PI: Nadler J/Casanas B                      2005-2008  
A randomized, controlled, partially blinded Phase IIb dose-finding trial of TMC125, in HIV-1 infected subjects with documented genotypic evidence of resistance to currently available NNRTIs and with at least three primary PI mutations
31. Tibotec (TMC125-C229)                      PI: Nadler J,/Casanas B                      2005-2008  
An Open-Label Trial with TMC125 in HIV-1 Infected Subjects, Who Were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and were Treated for at least 48 Weeks
32. GlaxoSmithKline (EPZ104057)                      PI: Nadler J/Casanas B                      2005-2008  
A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of Epzicom versus Truvada Administered in Combination



with Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects” [EPZ104057] – HEAT

33. GlaxoSmithKline (COL100758) PI: Nadler J/Casanas B 2005-2008  
A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908/Ritonavir Given with Abacavir/Lamivudine Fixed Dose Combination
34. Tibotec (TMC114-C214) PI: Nadler J/Montero J 2005-2008  
A Randomized, Controlled, Open-Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV versus LPV/RTV in Treatment-Experienced HIV-1 Infected Subjects
35. Tibotec (TMC114-C211) PI: Nadler J 2005-2006  
A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir. This trial will be referred to as ARTEMIS
36. Tibotec (TMC125-C217) PI: Nadler J/ Wills T 2005-2008  
A randomized, controlled, partially blinded Phase IIb dose-finding trial of TMC125, in HIV-1 infected subjects with documented genotypic evidence of resistance to currently available NNRTIs and with at least three primary PI mutations
- 37.** Tibotec (TMC125-C206) PI: Nadler J/ Casanas B 2006-2008  
A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR in HIV-1 infected subjects with limited to no treatment options
38. Merck (MK-0518-32) PI: Holt D 2006-2007  
A Multicenter, Double-Blind, Randomized, Active-Controlled Study to evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA
39. Gilead (GS-US-183-0105) PI: Wills T 2005-2007  
A Phase 2, Randomized Study of the Treatment of Antiretroviral Treatment-Experienced, HIV-1 Infected Subjects Comparing Ritonavir-Boosted GS-9137 (GS-9137/r) Versus a Comparator Ritonavir-Boosted Protease Inhibitor (CPI/r) in Combination with a Background Antiretroviral Therapy”
40. Kendle (NGX-4010-C119) PI: Wills T 2006-2007  
A Multicenter Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy
41. GlaxoSmithKline (EPZ 108859-ARIES) PI: Montero J 2006-2007  
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed Dose Combination Tablet (ABC/3TC FDC) for 36 weeks Followed by Simplification to Atazanavir with ABC/3TC FDC or

Maintenance of the Initial Regimen for Additional 48 Weeks in Antiretroviral Therapy Naïve HIV-1 Infected HLA-B\*5701 Negative Subjects

42. Merck (V520 – 014A) PI: Nadler  
J Probe Study to Evaluate the Safety, Tolerability, and Immunogenicity of the MRK Adenovirus Serotype 5 Vector (MRKAd5) Human Immunodeficiency Virus Type I (HIV-1) gag Vaccine in HIV-1 Infected Individuals
43. Schering-Plough PI: Nadler  
JPEG-Interferon  $\alpha$ -2b + Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-Infected Persons Not Previously Treated with Interferon. Hepatitis Resource Network HRN-005
44. Abbott (M06-802) PI: Nadler J  
A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Co-administered with Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-experienced, HIV-1 Infected Subjects
45. Agouron (AG-1549-509) PI: Nadler J  
A Phase II Double-blind, Randomized, Placebo-controlled study of Capravirine (AG1549) in combination with Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV-infected Subjects who failed an initial Nonnucleoside Reverse Transcriptase Inhibitor-containing Regimen
46. Bristol-Myers Squibb (BMS AI455-09) PI: Nadler J  
The Safety and Antiviral Efficacy of Stavudine Extended Release Formulation as Compared to Stavudine Immediate Release Formulation, Each as a part of Potent Antiretroviral Combination Therapy
47. Gilead Sciences (GS-99-910) PI: Nadler J  
A Phase 3, Open-label, Multicenter Study of the Safety of Tenofovir Disoproxil Fumarate Administered in Combination with Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients
48. GlaxoSmithKline (APV30001) PI: Nadler J  
A Phase III, randomized, multicenter, parallel, open-label study to compare the efficacy, safety, and tolerability of GW433908 1395 mg bid and Nelfinavir 1250 mg bid over 48 weeks in antiretroviral therapy naive HIV-1 Infected Adults
49. Bristol-Myers Squibb PI: Nadler J  
Resistance Testing of HIV-Infected Patients Entering Therapy. Bristol Myers Squibb
50. Bristol-Myers Squibb PI: Nadler J  
A Study to Compare Long-Term Safety and Tolerability of Stavudine (D4T) Extended Release (ER) Versus Conventional (Immediate Release, IR) Formulation, Each in Combination with Lamivudine (3TC) and Efavirenz (EFV) in Subjects Who Have Completed BMS Studies AI455-096 and AI455-099

51. GlaxoSmithKline PI: Nadler J  
Chart Review Study of Amprenavir Trough Levels in Patients Receiving Antiretroviral Therapy Including a Combination of Kaletra and Amprenavir
52. Gilead Sciences PI: Nadler J  
Develop a Database to Establish the Prevalence of Anemia in A Large Public Health Department HIV Specialty Clinic
53. GlaxoSmithKline (APV30005) PI: Nadler J  
An Open-Label, Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects
54. GlaxoSmithKline (APV30003) PI: Nadler J  
A Phase III, Randomized, Multicenter, Parallel Group, Open-label, Three Arm Study to Compare the Efficacy and Safety of Two Dosing Regimens of GW433908/ritonavir versus lopinavir/ritonavir for 48 Weeks in HIV-Infected Adults Experiencing Virological Failure
55. Abbott (MOO-267) PI: Nadler J  
Performance of Lopinavir/Ritonavir as an Alternative Treatment Option (PLATO): A randomized, Phase IV Study to Evaluate the Quality of Life of Subjects Infected with HIV-1 and Who Are Intolerant to Their Current Antiretroviral Therapy
56. Merck (V520 – 014) PI: Nadler J  
A Probe Study to Evaluate the Safety, Tolerability, and Immunogenicity of the MRK Adenovirus Serotype 5 Vector (MRKAd5) Human Immunodeficiency Virus Type I (HIV-1) gag Vaccine in HIV-1 Infected Individuals
57. Boehringer Ingelheim (1182.52) PI: Nadler J  
Double-blind, randomized, dose optimization trial of three doses of tipranavir boosted with low dose ritonavir (TPV/RTV) in multiple antiretroviral drug-experienced subjects
58. Boehringer Ingelheim (1182.17) PI: Nadler J  
A Long-Term Open-Label Rollover Trial Assessing the Safety and Tolerability of Combination Tipranavir and Ritonavir
59. Agouron (A4311002) PI: Nadler J  
A Double-Blind, Randomized, Placebo-Controlled Study of Two Doses of Capravirine (AG1549) in Combination with VIRACEPT™ and Two Nucleoside Reverse Transcriptase Inhibitors in HIV-infected Patients Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen
60. Achillion (ACH443-006) PI: Nadler J

A Phase 2 Trial of 4 Weeks of ACH-125,443 in Comparison with Continued Lamivudine in Stable Triple Antiretroviral Combination Therapy in HIV-Infected Subjects with Modestly Detectable Viral Load

61. Achillion (ACH443-902) PI: Nadler J  
An Open-Label Treatment Protocol to Provide Continued ACH126, 443 to Subjects of Previous Achillion-Sponsored Phase 2 Studies in HIV Infection
62. Bristol-Myers Squibb (AI455-135 ZEST-QD) PI: Nadler J  
A Phase IIIB, Open Label, Randomized, Multicenter Study Switching HIV-1 Infected Subjects with a Viral Load of < 50 copies/mL on a BID or more frequent Initial HAART Regimen to a Once Daily Regimen Including Stavudine XR, Lamivudine, and Efavirenz
63. Stanford University PI: Nadler J  
A Review of Adherence to U.S. Public Health Services/ Infectious Diseases Society of America Guidelines for the Care of HIV/Hepatitis C Co-Infected Patients. Stanford University CBIG
64. Agouron/Pfizer (A4311006) PI: Nadler J  
A Phase 2, Randomized, Double-Blind, Study of Capravirine (AG1549) in Combination with Kaletra and at Least 2 Nucleoside Reverse Transcriptase Inhibitors in HIV Infected Subjects Who Have Failed Antiretroviral Regimens
65. Boehringer Ingelheim PI: Nadler J  
Randomized, Open-Label, Comparative Safety and Efficacy Study of Tipranavir Boosted with Low-Dose Ritonavir (TPV/RTV) versus Genotypically-Defined Protease Inhibitor/ritonavir (PI/RTV) in Multiple Antiretroviral Drug-Experienced Patients (RESIST 1: Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients with Tipranavir)
66. Ortho Biotech (PR01-29-024) PI: Nadler J  
An Open-Labeled Study to Evaluate the Effect of Every Other Week PROCRI<sup>®</sup> (Epoetin alfa) Dosing on Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients
67. GlaxoSmithKline (ESS30009) PI: Nadler J  
A Phase III, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of Efavirenz QD Versus Tenofovir QD when Administered in Combination with the Abacavir/Lamivudine Fixed-Dose Combination Tablet QD in Antiretroviral-Naïve HIV-1 Infected Subjects.

**GRANTS:**

1. USF Hepatitis C Evaluation and Technical Assistance Center. HRSA.  
Funded \$3,000,000  
Role: Infectious Disease Specialist/Lead Clinician  
Location: USF  
2010-2014

2. Federal AIDS Drug Assistance Program- Hepatitis C Pilot Project for Polk County, 2004. Funded \$100, 000.  
Role: PI  
Location: Polk County Health Department  
2004-2006
3. Florida Department of Health, Polk Pathway to Human Resource Renewal: 2004-2005 Quality Management Demonstration Project. 2004. Funded \$7,500.  
Role: Co-Investigator  
Location: Polk County Health Department
4. Government Maharashtra, India and World Bank Fund: “Training Indian Physicians on HIV Care: A Capacity Building Grant”. 2005. Funded \$200,000  
Role: Coauthor  
Location: USF/India  
2005-2006

## **SERVICE**

### **University Committees and Services:**

- Member, ACGME Self-study committee, University of South Florida Morsani College of Medicine, Division of Infectious Diseases and International Medicine, 2018-present
- Faculty advisor, Tampa Bay Street Medicine, University of South Florida, 2016-2018
- Country Coordinator, USF Medicine International and Thai Colleges of Medicine, 2015-present
- Curriculum Committee, University of South Florida Morsani College of Medicine, Division of Infectious Diseases and International Medicine, 2014-present
- Senator, University of South Florida, Faculty Senate, 2012
- Member, University of South Florida Physician Group CEO and VP of Clinical Affairs Search Committee, 2010-2011
- Member, Medical Advisory Group. Office of Clinical Research, University of South Florida College of Medicine, 2010- 2013
- Faculty Advisor, Asia Pacific Medical Student Association, 2010-2014
- Country Coordinator, USF and Srinakharinwirot University, 2008-present
- Member, Diversity Committee, Department of Medicine, University of South Florida College of Medicine, 2007-present
- Member, University of South Florida Institutional Review Board, 2007-2013
- Host Physician for public health officials from the government of Maharashtra, India: CHART-INDIA, a collaborative project of Infectious Disease Division and College of Public Health, 2004

**Contracts:**

Florida Health Hillsborough County Physician Oversight Service: AIDS Patient Care, Communicable Disease Director, Chief of Medical Staff, Lab Director and HIV Research. Funded: \$613,365, 2019-present

Medical Director for Crisis Center of Tampa Bay. Funded \$ 16,000 annually, 2015-2020

Medical Director for Ryan White Service for Tampa General Health Care. Funded: \$15,000 annually

Expert Consultant, Molina Healthcare, Funded: up to \$10,000 annually, 2011-2015

Infectious Disease Services to North Tampa Outpatient Surgical Facility. Funded: \$5,000 annually, 2010-2014

Infectious Disease Services to Tampa Outpatient Surgical Facility. Funded: \$10,000 annually, 2008-2015

**Professional Committees and Services:**

Member, IDSA/HIVMA Ending HIV Epidemic Task Force, 2020-Present

Faculty Advisor, CLABSI Task Force and Quality Improvement Projects, Tampa General Hospital, Tampa Florida, 2017- 2019

Member, Executive Committee, University of Florida/NIAAA, Southern HIV and Alcohol Research Consortium, 2014-2018

Expert Reviewer, University of Miami, Miller's School of Medicine, Promotion and Tenure Committee, 2012-present

Member, Florida HIV Research Council Steering Committee, Research Education Sub-committee, 2011-present

Physician Volunteer, Back to School Event. Tampa, Florida. August 16, 2014

Physician Volunteer, High Resolution Anoscopy Clinic, Florida Department of Health, Hillsborough County. Provide anal cancer screening to patient with HIV infection, 2010-2016

Physician Preceptor Volunteer, High Resolution Anoscopy Training, Florida Department of Health, Hillsborough County. Provide training to physicians and mid-level providers in anal cancer screening and high resolution anoscopy, 2013-2016

Physician Volunteer, Back to School Event. Tampa, Florida. August 4, 2012

Physician volunteer: Multiple Asian Health Fairs, Provide medical supervision to USF medical students in health education and screening for Asian people in Bay area, particularly for those with language barrier or indigent, 2006-present

Member, *Thai Physician Association of America, Southern Chapter*, 2005-present

Member, Florida Department of Health Institutional Review Board, 2005-2011  
Member, *Polk County Health Department's Leadership Council* and the *Sterling Subcommittee*, 2003-2006  
Member, Examining Committee, Sunrise Community Cluster Home, 2003-2006  
Physician volunteer in "Thai Health". Provide health education and screening for Thai people in New York City and New Jersey area, for those who have language barriers or have no health care coverage, 2001  
Member, *Resident Ethics Committee* at St. John's Episcopal Hospital, 1999-2001  
Member, *Geriatric Multidisciplinary Committee*, Ramathibodhi Hospital, 1996-1998  
Member, Faculty Student Network Committee, 1989-1995

### **Community Service:**

Member, Ending the HIV Epidemic Working Group. HIV Medicine Association. 2020-present  
Member, Infectious Disease Association of America Leadership Institution Selection Taskforce. 2019-2020  
Member, Fast-track Cities Tampa Bay Oversight Committee. 2019-2021  
Member, Fast-track Cities Tampa Bay, Substance Use Disorder including Persons who inject Drugs sub-committee. 2019-2021  
Member, Tampa Bay Area Committee of Foreign Relation, 2014-present  
Member, Diversity Task Force. Planned Parenthood National. 2010-2011  
Featured in 83 Degrees, Timeless Friendship Bridges Generations, Cultures for Tampa Women (<http://www.83degreesmedia.com/features/friends091410.aspx>), September 14, 2010  
Featured in University Beat, HIV Clinical Research. January 2009  
Member, Board of Directors, Planned Parenthood of Southwest and Central Florida. 2008-2014  
Member, Leadership Florida Cornerstone Class XXVI Selection Committee, 2007  
Judge, Third Annual Florida Cities of Excellence Award, Florida League of Cities, 2006  
Member, Incident Command System (IS 100, IS 200 and IS 700), Federal Emergency Management Agency, 2005-2006  
Chief Medical Officer, Incident Command System for Influenza Vaccine Shortage, 2004-2005  
Operation Section Chief and Medical Officer in Incident Command System during Hurricane Charley, Hurricane Frances, Hurricane Ivan, and Hurricane Jeanne, 2004  
Increasing Proficiency of Patient Care Clinic Medical Records System: Patient Care Clinic, Bartow, Florida, 2004

Physician, leader, mobile medical unit for Hurricane victims, Hardee County, Florida, 2004

Developing tools to evaluate Quality of Care: Polk County Health Department Clinic Sites, 2003

Polk Health Department and University of South Florida Representative: Polk County Medical Association, 2003

Physician volunteer, "NBC Phone Bank Programs". Provide information regarding Bioterrorism and Viral Hepatitis to communities in Tampa Bay and surrounding areas, 2001

Member, Incident Command System Orientation, Florida Department of Law Enforcement, Tampa, Florida, 2001

Physician volunteer in underserved area of Bangkok, 1997-1998

Representative, Thai Medical Doctor Distribution Congress, 1995

### **Society Memberships:**

International Anal Neoplasia Society, 2013-2017

Hillsborough County Medical Association, 2012-2014

Florida Public Health Association, 2007-present

Leadership Florida, Lifetime Member, 2007-present

Thai Physicians Association of America, 2005-present

Polk County Medical Association, 2003-2006

Florida Infectious Diseases Society, 2002-present

Infectious Diseases Society of America, 2001-present

American Medical Association, 1998-present

American College of Physicians, 1998-present

The Medical Council of Thailand, 1995-present

### **Philanthropy:**

White Coat Sponsor. University of South Florida, Morsani College of Medicine. 2013-present

WUSF Public Radio, Sustaining Member. 2013-present

John T Sinnott Scholarship, founding contributor and fundraiser. University of South Florida, Morsani College of Medicine. 2012

Fundraiser, Delia Sanchez Scholarship (over \$20,000), Ybor Museum Society and Hillsborough Community College. Scholarship released March 25, 2011

US Peace Memorial Foundation, founding member. 2010

Alpha Omega Alpha Honor society. 2009-present



Youth Table Sponsor: Choice Affair Lunch for Planned Parenthood of Southwest Central Florida. 2009-present